Martin Gill serves as senior vice president and head of research for Libra Therapeutics, where he advances portfolio programs from high-throughput screening into clinical development and identifies and validates new targets for delivering disease-modifying therapies for central nervous system (CNS) indications with high unmet medical need. Prior to joining Libra Therapeutics, Dr. Gill served as head of in vitro discovery at Neuropore Therapies, which focused on identifying and advancing small molecule-targeted mechanisms that reduce CNS inflammation and protein pathology associated with Parkinson’s disease and amyotrophic lateral sclerosis (ALS). He also spent five years at Bristol Myers Squibb, where he served as project lead for traditional small molecule portfolio programs, as well as novel therapeutic portfolio programs, targeting pathogenic mechanisms associated with neurodegeneration. Dr. Gill received his PhD from the University of Texas Medical Branch and conducted postdoctoral fellowships at Northwestern University, Feinberg School of Medicine and Eli Lilly and Company.